Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
  • Publication Type:
    Journal article
  • Authors:
    Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H, Abbott A, Abbott A, Abdallah N, Abdelaziz A, Abdelaziz A, Abdelfattah M, Abdelqader B, Abdul A, Abdul B, Abdul S, Abdul Rasheed A, Abdulakeem A, Abdul-Kadir R, Abdullah A, Abdulmumeen A, Abdul-Raheem R, Abdulshukkoor N, Abdusamad K, Abed El Khaleq Y, Abedalla M, Ul Amna A, Abel L, Abernethy K, Abeywickrema M, Abhinaya C, Abidin A, Aboaba A, Aboagye-Odei A, Aboelela H, Abo-Leyah H, Abouelela K, Abou-Haggar A, Abouibrahim M, Abousamra A, Abouzaid M, Abraham M, Abraham T, Abraheem A, Abrams J, Abrams R, Abu HJ, Abu-Arafeh A, Abubacker SM, Abung A, Abusamra Y, Aceampong Y, Achara A, Acharya D, Acheampong P, Acheampong S, Acheson J, Achieng S, Acosta A, Acquah R, Acton C, Adabie-Ankrah J, Adair P, Adam F, Adam M, Adamali H, Adamczyk M, Adams C, Adams C, Adams D, Adams K, Adams L, Adams N, Adams R, Adams T, Adamu-Ikeme L, Adatia K, Adcock K, Addo A, Adeagbo O, Adebiyi A, Adedeji O, Adegeye Y, Adegoke K, Adell V, Adenwalla S, Adeoye FW, Adesemoye OA, Adewunmi EO, Adeyanju A, Adeyemi J, Adeyemo T, Adhikari B, Adhikary R, Aditya A, Adkins G, Adnan A, Aeron-Thomas J
  • Publisher:
    Elsevier BV
  • Publication date:
  • Pagination:
    359, 368
  • Journal:
    The Lancet
  • Volume:
  • Issue:
  • Medium:
  • Status:
  • Country:
  • PII:
  • Language:
  • Keywords:
    Azetidines, COVID-19, Hospitals, Humans, Janus Kinase Inhibitors, Purines, Pyrazoles, Randomized Controlled Trials as Topic, SARS-CoV-2, Sulfonamides, Treatment Outcome
  • Notes:
    This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was done, which included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. The RECOVERY trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936) and is ongoing. Findings: Between Feb 2 and Dec 29, 2021, from 10 852 enrolled, 8156 patients were randomly allocated to receive usual care plus baricitinib versus usual care alone. At randomisation, 95% of patients were receiving corticosteroids and 23% were receiving tocilizumab (with planned use within the next 24 h recorded for a further 9%). Overall, 514 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0·87; 95% CI 0·77–0·99; p=0·028). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of eight previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths), in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0·57; 95% CI 0·45–0·72). Including the results from RECOVERY in an updated meta-analysis of all nine completed trials (involving 11 888 randomly assigned patients and 1485 deaths) allocation to baricitinib or another JAK inhibitor was associated with a 20% proportional reduction in mortality (rate ratio 0·80; 95% CI 0·72–0·89; p<0·0001). In RECOVERY, there was no significant excess in death or infection due to non-COVID-19 causes and no significant excess of thrombosis, or other safety outcomes. Interpretation: In patients hospitalised with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials. The total randomised evidence to date suggests that JAK inhibitors (chiefly baricitinib) reduce mortality in patients hospitalised for COVID-19 by about one-fifth. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers Show More
UCL EGA Institute for Womens Health
Div of Infection & Immunity
Renal Medicine
Institute for Global Health
Inst of Clinical Trials &Methodology
Experimental & Translational Medicine
Infection, Immunity & Inflammation Dept
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by